The Marijuana Herald

Daily Cannabis News Brief for 8/26/2026

Below is The Marijuana Herald’s Daily Cannabis News Brief for August 26, 2026. The Marijuana Herald publishes a new edition every weekday at around 3 p.m. Pacific Time. You can find previous editions by clicking here.

Washington Cannabis Stores Far Outperform Alcohol and Tobacco Retailers in 2026 Youth Compliance Checks

Washington marijuana stores have passed 92.5% of youth compliance checks conducted in 2026, compared with 84.7% for tobacco retailers and 82.7% for alcohol retailers. Just 7.5% of marijuana compliance checks resulted in an illegal sale, less than half the 15.3% failure rate for tobacco retailers and 17.3% rate for alcohol retailers, continuing a longstanding pattern of higher compliance among licensed marijuana stores.

Cannabis Finance Executives React to DEA Rescheduling Transcripts

Cannabis finance executives Anthony Coniglio of NewLake Capital Partners, Terry Mendez of Safe Harbor and Adam Stettner of FundCanna weighed in on the Drug Enforcement Administration’s (DEA) recently released marijuana rescheduling hearing transcripts. The executives highlighted the federal government’s acknowledgment of marijuana’s accepted medical use, the potential elimination of the 280E tax burden under Schedule III and the broader financial benefits rescheduling could bring, while emphasizing that significant regulatory and legal steps remain.

CDC Proposes Marijuana Use Questions for 2028 National Health Interview Survey

The Centers for Disease Control and Prevention (CDC) is proposing to add questions about marijuana use to the 2028 National Health Interview Survey. Adults would be asked how often they currently use marijuana and whether they consume it for reasons including recreation, pain relief, nausea, anxiety or stress, sleep or other medical purposes. The questions remain proposals and could be modified before implementation.

Federal Appeals Court Says Vacated Marijuana Conviction Cannot Be Used for Immigration Removal

The U.S. Court of Appeals for the Fourth Circuit ruled that a vacated marijuana possession conviction can no longer be used to classify someone as “convicted of” a controlled-substance offense for immigration purposes. The court rejected a longstanding Board of Immigration Appeals policy that allowed some vacated convictions to continue carrying immigration consequences depending on why they were erased.

JARS Cannabis to Acquire Sonoran Roots, Creating 27-Store Arizona Marijuana Retail Network

JARS Cannabis has reached an agreement to acquire Arizona-based Sonoran Roots, a transaction that would give the combined company 27 dispensaries across the state and create what the companies say will be Arizona’s largest marijuana retail network. Sonoran Roots’ eight Ponderosa Dispensary locations will eventually transition to the JARS brand, while its existing marijuana brands will remain in operation. The acquisition is expected to close by the end of the third quarter of 2026.

Aurora Investors Overwhelmingly Oppose Curaleaf Takeover Bid, While Curaleaf Investors Back Deal, Finds Informal Poll

Aurora Cannabis investors appear overwhelmingly opposed to Curaleaf’s takeover bid, while Curaleaf investors are considerably more supportive, according to an informal poll conducted by The Marijuana Herald. Among 50 self-identified Aurora investors, 90% opposed the current offer, while 64% of 50 self-identified Curaleaf investors supported the proposed acquisition. The poll was informal and not scientific, and respondents’ ownership of shares was not independently verified.

Review Finds Cannabis Compounds Show Strong Anticancer Effects Against Cervical Cancer Cells

Cannabis compounds including CBD and THC showed anticancer activity against cervical cancer cells across multiple laboratory studies, including triggering cancer cell death and reducing invasion, according to a review published in the Journal of Cannabis Research. Researchers identified five qualifying studies, all involving cell cultures, and cautioned that animal and human research is still needed before the compounds’ potential therapeutic effectiveness can be established.